Cx45 regulation by kinases and impact of expression in heart failure

Gaelle Spagnol1, Andrew Trease1, Li Zheng1

  • 1From the Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Insights

This study reveals how c-Src phosphorylates Cx45 in heart disease, impacting connexin function. Aberrant Cx45 expression may contribute to cardiac dysfunction by altering Cx43 localization and channel permeability.

Area of Science:

  • Cardiovascular Biology
  • Cell Signaling
  • Molecular Cardiology

Background:

  • Phosphorylation regulates connexin function, including gap junction intercellular communication (GJIC), localization, and stability.
  • Specific kinases and phosphorylation sites for connexin 45 (Cx45) are largely unknown, hindering understanding of its role in cardiac disease.

Purpose of the Study:

  • To identify kinases that phosphorylate Cx45 and their target residues.
  • To investigate the functional consequences of Cx45 phosphorylation by c-Src in the context of heart disease.
  • To elucidate the role of Cx45 in Cx43 regulation and cardiac dysfunction.

Main Methods:

  • Phosphorylation screening and mass spectrometry to identify Cx45-targeting kinases and residues.
  • Cellular assays (LA-25 cells) to assess GJIC, protein localization, and interactions.
  • Use of phospho-specific antibodies to analyze connexin phosphorylation patterns.
  • In vivo studies using a rat model of heart failure.

Main Results:

  • c-Src phosphorylates Cx45 at tyrosine residues Y324 and Y356.
  • Unlike Cx43, c-Src phosphorylation of Cx45 does not impair GJIC, junctional localization, or cytoskeletal interactions.
  • Cx45 expression maintains Cx43 at the plasma membrane in v-Src-activated LA-25 cells.
  • In heart failure, Cx45 is expressed in ventricles, co-localizes with Cx43, and alters dye coupling, suggesting a shift towards Cx45-like channel permeability.
  • Cx43 phosphorylation patterns favor turnover (tyrosine) or GJIC (serine).

Conclusions:

  • c-Src activation alone does not adversely affect Cx45 function in heart failure.
  • Aberrant Cx45 expression aids Cx43 transport and maintenance at the intercalated disc.
  • Dominant effects of Cx45 in heteromeric channels may drive cardiac dysfunction.
  • Kinase regulation of connexins is isoform-specific, as Cx45-mediated coupling remains functional where Cx43 coupling is inhibited.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321